Abstract: Systems, methods and tools for the interrogation of fiber-reinforced composite strength members to assess the structural integrity of the strength members. The systems and methods utilize the transmission of light through optical fibers that are embedded along the length of the strength members. The inability to detect light through one or more of the optical fibers may be an indication that the structural integrity of the A strength member is compromised. The systems and methods may be implemented without great difficulty and may be implemented at any time in the life cycle of the strength member, from production through installation. The systems and methods have particular applicability to bare overhead electrical cables that include a fiber-reinforced strength member.

Abstract: An apparatus (1) for cooling containers, in particular vials, comprising at least one first cooling zone (200) for receiving containers, with a cooling zone base and a cooling zone wall (201), and a cooling device (300) for cooling air, and a first duct (113) for conducting the cooled air from the cooling device (300) into the cooling zone (200), wherein an outlet of the first duct (113) is spaced apart from the cooling zone base.

Abstract: An electrical train messenger wire and a catenary system for an electrical train including the electrical train messenger wire. The messenger wire includes a fiber-reinforced composite strength member and a conductive layer surrounding the fiber-reinforced composite strength member, where the conductive layer is fabricated from copper or a copper alloy. The fiber-reinforced strength member advantageously has a high tensile strength, thereby reducing the sag of a contact wire supported by the messenger wire. The catenary system employing the messenger wire may facilitate faster train speeds and may obviate the need for cantilever systems such as balanced weight anchors to maintain tension in the contact wire.

Abstract: A termination arrangement for securing an overhead electrical cable to a dead-end structure such as a dead-end tower. The termination arrangement includes a compression sheath that is configured to be disposed between a strength member and the conductive strands of the overhead electrical cable. The compression sheath mitigates damage to the strength member that may occur when an outer metallic sleeve is compressed around the conductive strands and the conductive strands are compressed against the strength member. The arrangement is particularly useful for securing overhead electrical cables having a composite strength member to a dead-end structure.

Abstract: Aspects of the present disclosure relate to methods and compositions for sugarcane transformation using morphogenic genes. In particular, the present disclosure relates to the use of morphogenic sequences that improve the efficiency of sugarcane cell or tissue transformation and genomic modification. The present disclosure further relates to genetically altered sugarcane cells, tissues, and plants produced using these methods and compositions.

Abstract: In a process for thermally desorbing a phase material (20), in particular for conditioning a fiber for carrying out a solid-phase microextraction, the phase material (20) is heated along a temperature curve. The temperature curve of the phase material (20) during desorption includes at least one low point.

Abstract: The present disclosure relates to an orally administered pharmaceutical formulation containing an inclusion complex formed as varenicline or a pharmaceutically acceptable salt thereof is included in cyclodextrin. The pharmaceutical formulation can improve convenience of medication by effectively masking the bitter taste of the drug and the irritation during swallowing, can provide the oxidation stability of varenicline and can improve the solubility of the drug.

Abstract: A method for automated processing of a sample using a first pipette tip container (110) having a first pipette tip comprises the steps of: removing the first pipette tip (160) from the first pipette tip container (110); feeding the sample into the first pipette tip container (110); processing the sample in the first pipette tip container (110). A rack (100) comprises at least one first pipette tip container (110) having a first pipette tip (160), wherein the rack (100) comprises means for identifying an alignment of an orientation of the rack (100) in a rack receptacle of an apparatus for automated processing of a sample. A transport arrangement comprises at least two racks (100), wherein at least one bottom region of a pipette tip container (110) of a first rack (100) is in direct contact with a releasable covering, in particular a tear-off film of a second rack (100).

Abstract: The present disclosure relates to a film formulation for oral administration, containing tadalafil free base and a method of preparing the same, and a film may be provided with maximized dispersion stability of tadalafil free base in the film by the addition of a dispersion stabilizing agent in small amounts without unique fragrance or favor that may appear when other dispersion stabilizing agents known in the art are used, and an extremely low likelihood that a reagglomeration phenomenon of tadalafil free base particles will occur, and an amount of bubbles generated may be significantly reduced during a production process.

Abstract: A release mechanism generates a force on a cable to operate an adjustment mechanism or the like in a seat or other device. The release mechanism includes a rotor, a housing, a spring, and a cover that attaches to the housing. The spring generates a torque, and the spring also axially biases the rotor into engagement with the cover to prevent rattling.

Abstract: The present application concerns a cartridge with a housing and at least one reaction well for a chemical or a biological assay arranged on an outside surface of said housing. The at least one reaction well has a bottom surface, preferably coated with at least one chemical or biological binding agent suitable to bind to a component to assay the presence of a component in a probe. Said cartridge further comprises at least one storage vessel arranged in said housing. The at least one storage vessel comprises a reagent solution, wash solution and/or dilution solution in a quantity which is sufficient to carry out the assay in said at least one reaction well, the number of storage vessels of said cartridge being chosen such that all reagent solutions, wash solutions and/or dilution solutions needed to carry out the assay in said at least one reaction well are present in said cartridge.

Abstract: A method for operating a dosing device comprising a control unit, a dosing unit with a cannula of a first volume, and a sampling container connected to the cannula. The method comprises moving the dosing unit in a first direction along an axis to move the cannula into a vessel containing a liquid; constantly aspirating fluid through the cannula with a predetermined volumetric flow; measuring at least one optical parameter of the aspirated fluid; when a change of the optical parameter is detected, storing a first position of the dosing unit on the axis and interrupting the movement of the dosing unit; and calculating a second position of the dosing unit on the axis at which the tip of the cannula has penetrated a first phase boundary upon immersion into the liquid. The calculation is performed on the basis of the first position, the predetermined speed, the first volume and the predetermined volumetric flow.

Abstract: A release mechanism generates a force on a cable to operate an adjustment mechanism or the like in a seat or other device. The release mechanism includes a rotor, a housing, a spring, and a cover that attaches to the housing. The spring generates a torque, and the spring also axially biases the rotor into engagement with the cover to prevent rattling.

Abstract: The present disclosure relates to a pharmaceutical preparation having varenicline or a pharmaceutically acceptable salt thereof as an active ingredient. More particularly, it relates to an orally administered pharmaceutical preparation which allows limited use of a sweetening agent or a flavoring agent by effectively masking the unique taste of varenicline, particularly bitterness, which is a bitter and burning taste, and ensures convenience in taking the pharmaceutical preparation by being orally administrable without irritation, while containing a pharmaceutically effective amount of varenicline or a pharmaceutically acceptable salt thereof, and a method for preparing the same.

Abstract: An apparatus (1) for cooling containers, in particular vials, comprising at least one first cooling zone (200) for receiving containers, with a cooling zone base and a cooling zone wall (201), and a cooling device (300) for cooling air, and a first duct (113) for conducting the cooled air from the cooling device (300) into the cooling zone (200), wherein an outlet of the first duct (113) is spaced apart from the cooling zone base.

Abstract: A release mechanism generates a force on a cable to operate an adjustment mechanism or the like in a seat or other device. The release mechanism includes a rotor, a housing, a spring, and a cover that attaches to the housing. The spring generates a torque, and the spring also axially biases the rotor into engagement with the cover to prevent rattling.

Abstract: In a process for thermally desorbing a phase material (20), in particular for conditioning a fiber for carrying out a solid-phase microextraction, the phase material (20) is heated along a temperature curve. The temperature curve of the phase material (20) during desorption includes at least one low point.

Abstract: The present invention provides a pharmaceutical formulation comprising clomipramine or its pharmaceutically acceptable salt (preferably, clomipramine hydrochloride) as the first active ingredient, and sildenafil or its pharmaceutically acceptable salt (preferably, sildenafil citrate) as the second active ingredient, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation. In particular, the present invention provides a pharmaceutical formulation comprising the above two active ingredients and manufactured by using a wet granulation method, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation.

Abstract: A device for activating a screw cap of a container comprises a first holding device for holding the screw cap, and a drive for activating the first holding device, wherein the first holding device is movable in a plane. The first holding device comprises a coupling device for the coupling of an external drive, and therefore the first holding device is movable in the plane.

Abstract: An industrial process using kestose hydrolases to enable the use of sugar mixtures containing 1-kestose in the industrial production of sucrose (as crystallized sugar) by providing a method for the conversion of 1-kestose into sucrose and fructose in a sugar solution, containing kestose and more than 10 mM sucrose (3 g/L), and comprising the enzymatic hydrolysis (preferably using 1-FEH enzymes—EC 3.2.1.153) of 1-kestose. The process further provides a method of producing a polypeptide having 1-kestose hydrolase activity and a composition comprising the polypeptide.